Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2021;71(3):703–249.
   Web of Science ®Google Scholar
• American Cancer Society. Lung cancer survival rates; 2021. [cited 2021 June 15] Available from: https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html.
   Google Scholar
• Kaira K, Takahashi T, Murakami H, et al. Long-term survivors of more than 5 years in advanced non-small cell lung cancer. Lung Cancer. 2010;67(1):120–123.
   PubMed Web of Science ®Google Scholar
• Lissoni P, Chilelli M, Villa S, et al. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res. 2003;35(1):12–15.
   PubMed Web of Science ®Google Scholar
• Noone A, Howlader N, Krapcho M, et al. SEER Cancer Statistics Review (CSR) 1975-2015; 2018. [cited 2021 October 26] Available from: https://seer.cancer.gov/archive/csr/1975_2015/.
   Google Scholar
• Borghaei H, Gettinger S, Vokes EE, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated Non-Small-Cell lung cancer. J Clin Oncol. 2021;39(7):723–733.
   PubMed Web of Science ®Google Scholar
• Gettinger S, Horn L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol. 2018;36(17):1675–1684.
   PubMed Web of Science ®Google Scholar
• OPDIVO (nivolumab), [prescribing information]; 2021. Bristol Myers Squibb: Princeton, NJ.
   Google Scholar
• YERVOY (ipilimumab), [prescribing information]; 2020. Bristol Myers Squibb: Princeton, NJ.
   Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480–489.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–1546.
   PubMed Web of Science ®Google Scholar
• Tannir NM, Frontera OA, Hammers HJ, et al. Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N + I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2019;37(7_suppl):547–547.
   PubMed Web of Science ®Google Scholar
• Yau T, Kang Y-K, Kim T-Y, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 2020;6(11):e204564.
   PubMed Web of Science ®Google Scholar
• Lenz H-J, Lonardi S, Zagonel V, et al. Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: clinical update. J Clin Oncol. 2020;38(4_suppl):11–11.
   PubMed Web of Science ®Google Scholar
• Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375–386.
   PubMed Web of Science ®Google Scholar
• Chau I, et al. Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first results of the CheckMate 648 study. J Clin Oncol. 2021;39(18_suppl):LBA4001.
   Web of Science ®Google Scholar
• Hellmann MD, Ciuleanu T-E, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020–2031.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Ciuleanu TE, Pluzanski A, et al. Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: three-year update from CheckMate 227 part 1. J Clin Oncol. 2020;38(15_suppl):9500–9500.
   Google Scholar
• US Food & Drug Administration, FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%). 2020.
   Google Scholar
• Latimer NR. NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data; 2011. [updated 2013 March; cited 2021 July 8]. Available from: https://www.sheffield.ac.uk/sites/default/files/2022-02/TSD14-Survival-analysis.updated-March-2013.v2.pdf.
   Google Scholar
• National Institute for Health and Care Excellence. NICE technology appraisal guidance [TA531]: pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer; 2018. [updated 2021 February 13; cited 2021 June 15]; Available from: https://www.nice.org.uk/guidance/ta531/resources/pembrolizumab-for-untreated-pdl1positive-metastatic-nonsmallcell-lung-cancer-pdf-82606895901637.
   Google Scholar
• Chaudhary MA, Lubinga SJ, Smare C, et al. Cost-effectiveness of nivolumab in patients with NSCLC in the United States. Am J Manag Care. 2021;27(8):e254–e260.
   PubMed Web of Science ®Google Scholar
• Huang M, Lou Y, Pellissier J, et al. Cost effectiveness of pembrolizumab vs. standard-of-care chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in the United States. Pharmacoeconomics. 2017;35(8):831–844.
   PubMed Web of Science ®Google Scholar
• Insinga RP, Vanness DJ, Feliciano JL, et al. Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US. J Med Econ. 2018;21(12):1191–1205.
   PubMed Web of Science ®Google Scholar
• Insinga RP, Vanness DJ, Feliciano JL, et al. Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US. Curr Med Res Opin. 2019;35(7):1241–1256.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Ganiats TG, Russell LB, et al. Cost effectiveness in health and medicine. Second ed. 2017. Oxford; New York: Oxford University Press: Oxford Scholarship Online.
   Google Scholar
• Rutherford MJ, Lambert PC, Sweeting MJ, et al. NICE DSU technical support document 21: flexible methods for survival analysis. Report by the Decision Support Unit; 2020. [cited 2021 July 8]. Available from: https://nicedsu.sites.sheffield.ac.uk/tsds/flexible-methods-for-survival-analysis-tsd.
   Google Scholar
• Gettinger S, Borghaei H, Brahmer J, et al. OA14.04 Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC. J Thorac Oncol. 2019;14(10):S244–S245.
   Web of Science ®Google Scholar
• Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43(3):203–220.
   PubMed Web of Science ®Google Scholar
• Weng X, Luo S, Lin S, et al. Cost-utility analysis of pembrolizumab versus chemotherapy as first-line treatment for metastatic non-small cell lung cancer with different PD-L1 expression levels. Oncol Res. 2020;28(2):117–125.
   PubMed Web of Science ®Google Scholar
• Criss SD, Mooradian MJ, Watson TR, et al. Cost-effectiveness of atezolizumab combination therapy for first-line treatment of metastatic nonsquamous non-small cell lung cancer in the United States. JAMA Netw Open. 2019;2(9):e1911952.
   PubMed Web of Science ®Google Scholar
• US Bureau of Labor Statistics. Consumer price index; 2021. [updated 2021 March 17; cited 2021 June 15]. Available from: https://www.bls.gov/cpi/data.htm.
   Google Scholar
• Bremner KE, Krahn MD, Warren JL, et al. An international comparison of costs of end-of-life care for advanced lung cancer patients using health administrative data. Palliat Med. 2015;29(10):918–928.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Nivolumab for previously treated squamous non-small-cell lung cancer [TA483]; 2017. [updated 2018 May 28; cited 2021 May 15]. Available from: https://www.nice.org.uk/guidance/ta483.
   Google Scholar
• National Institute for Health and Care Excellence. Nivolumab for previously treated non-squamous non-small-cell lung cancer [TA484]; 2017. [updated 2018 May 28; cited 2021 May 15]. Available from: https://www.nice.org.uk/guidance/ta484.
   Google Scholar
• National Institute for Health and Care Excellence. NICE technology appraisal guidance [TA655]: nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy; 2020. [updated 2021 June 15; cited 2021 June 15]. Available from: https://www.nice.org.uk/guidance/ta655.
   Google Scholar
• Marseille E, Larson B, Kazi DS, et al. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118–124.
   PubMed Web of Science ®Google Scholar
• Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163(14):1637–1641.
   PubMed Web of Science ®Google Scholar
• Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist. 2006;11(2):90–95.
   PubMed Web of Science ®Google Scholar
• Becker G, Murphy K, Philipson T. The value of life near its end and terminal care. National Bureau of Economic Research working paper No. 13333. August; 2007. [cited 2015 June 15]. Available from: https://www.nber.org/system/files/working_papers/w13333/w13333.pdf.
   Google Scholar
• Courtney PT, Yip AT, Cherry DR, et al. Cost-effectiveness of nivolumab-ipilimumab combination therapy for the treatment of advanced non-small cell lung cancer. JAMA Netw Open. 2021;4(5):e218787.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang T, Xu Y, et al. Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC. Immunotherapy. 2020;12(14):1067–1075.
   PubMed Web of Science ®Google Scholar
• Hu H, She L, Liao M, et al. Cost-effectiveness analysis of nivolumab plus ipilimumab vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer. Front Oncol. 2020;10:1649.
   PubMed Web of Science ®Google Scholar
• Goeree R, Villeneuve J, Goeree J, et al. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes. J Med Econ. 2016;19(6):630–644.
   PubMed Web of Science ®Google Scholar
• Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004–2012.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Cancer Query System: SEER survival statistics; 2021. [cited 2021 June 15]. Available from: https://seer.cancer.gov/canques/survival.html.
   Google Scholar
• Bristol Meyers Squibb. Four-year data from phase 3 CheckMate-227 trial show durable, long-term survival with Opdivo (nivolumab) plus Yervoy (ipilimumab) in patients with non-small cell lung cancer with PD-L1 expression ≥1%. 2021.
   Google Scholar
• Federal Reserve Economic Data. Consumer Price Index for All Urban Consumers: Medical Care in U.S. City Average; 2022. [cited 2022 February 28]. Available from: https://fred.stlouisfed.org/series/CPIMEDSL.
   Google Scholar
• Kluwer W. Medi-Span PriceRx database; 2021. [cited 2021 February 13]. Available from: https://pricerx.medispan.com.
   Google Scholar
• Centers for Medicare and Medicaid Services 2019 CMS clinical laboratory fee schedule; 2019.
   Google Scholar